CureVac N.V.
CVAC · NASDAQ
11/24/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 39,570.8% | 39.4% | -93.8% | – |
| Cost of Goods Sold | -$0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 95.8% | -77.8% | 2% | 89.7% |
| R&D Expenses | -$0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | -$0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | -$0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | -$0 |
| Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 74.6% | -4,959.5% | -6,128.4% | -302.4% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | $0 | -$0 |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 68.4% | -4,783.9% | -5,832.5% | -226.4% |
| EPS | 1.5 | -0.26 | -0.23 | -0.15 |
| % Growth | 676.9% | -13% | -53.3% | – |
| EPS Diluted | 1.5 | -0.26 | -0.23 | -0.15 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 0% | -4,417.1% | -5,234.6% | -241.2% |